Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,575.56
(
-0.74%
)
US TECH 100
23,629.20
(
-0.70%
)
Dow Jones
45,809.63
(
-0.90%
)
Brent Oil
108.83
(
2.11%
)
Bitcoin
69,209.01
(
-2.85%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rkrw post# 77323

Tuesday, 05/05/2009 8:38:04 PM

Tuesday, May 05, 2009 8:38:04 PM

Post# of 257259
Inasmuch as Teva’s new “low volume” formulation made its appearance after the patent challenge by NVS/MNTA on the seven Copaxone patents in the Orange Book, I think we can infer that Teva thinks the low-volume formulation will be protected by an altogether different patent.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now